|Day Low/High||6.00 / 7.25|
|52 Wk Low/High||4.50 / 13.80|
Compelling Advantages of Pressure BioSciences' Patented PCT Platform Prominently Featured in Multiple Presentations at Same International Conference
OTC Markets Group, President and CEO R. Cromwell Coulson, will speak on panel "Understanding Reg A+ and the 'Mini IPO'"
Investors in Final Close Include All Five Board Members
SCIEX Seminar Will Focus on Using Industrialized Omics to Perform Translational Research Needed to Enable Precision Medicine
SCIEX, a global leader in life science analytical technologies, today announced an exclusive co-marketing agreement with Pressure BioSciences, Inc.
Collaboration Will Combine the Advantages of PBI's PCT Platform with the Forensic Experience and Expertise of FIU, with a Goal to Help Reduce the Rape Kit Testing Backlog
Key Protein Scientists Report Unique Benefits of the PCT Platform in the Analysis of Critical Samples, Such as Cancer Tissue Biopsies and Stem Cells
Senior Secured Convertible Debenture Offering Closed at Market Price with Common Stock Warrants Exercisable at a 43% Premium; Proceeds Will Support Expansion of Marketing and Sales Team and Pay-down of Convertible Debt
Novel PCT-enhanced Method for Selective Extraction of DNA from Male or Female Cells Collected on Cotton Swabs Published in Major Scientific Journal
Conference Will Introduce Key European Institutional Investors to Executives from Leading MicroCap Companies within the Global Life Sciences Universe
Results of Studies by Three Key Opinion Leader Laboratories Demonstrate Significant Advantages in Drug Discovery, Cancer Detection, and in the Analysis of Microorganism Diversity in Soil
Scientists from the Northwestern University's Feinberg School of Medicine Report on the Development of an Enhanced Method for Determining Fetal Exposure to Maternal Smoke and Potentially Other Environmental Pollutants Using the Recently Released Barozyme HT48 System. Company Believes These New Applications Will Help Drive Revenue in 2015 and Beyond.
Evaluation of PBI's New High-Throughput PCT-based System Commences at a Top Ranked U.S. Medical School
Evaluations of PBI's New High-Throughput PCT-based System Underway at a World Renowned Academic/Research Institution and a Leading Biotechnology Company. Additional Evaluations at Key Opinion Leader Laboratories Scheduled.
PCT-dependent Method Provides High Quality Mass Spectrometry-based Proteomic Analysis in Small Needle Biopsy Samples for the First Time, Offering Potential to Vastly Improve Drug Discovery and Design Programs and Diagnostic Insights in Research and Clinical Laboratories Worldwide
Powertech Offers Strong Distribution and Support Network of 20 Offices/Laboratories, Over 60 Sales/Marketing/Service/Engineering Staff, and Multiple Sub-dealers Throughout China
Conference Expected to Bring Together Executives from Leading MicroCap Companies Within the Global Life Sciences Universe with European Institutional Investors
The Company Expects to Build and Ship Nine Instrument Systems for Evaluation between Mid-October and Late November. The Company Believes One or More Systems will be Purchased by the Evaluating Laboratories, Impacting Q4 2014 Revenue
David Weild IV, Former Vice Chairman of the NASDAQ Stock Market and Wall Street Veteran, and Edward H. Kim, Former Sr. Vice President of NASDAQ and Biotech Analyst, to Advise the Company on Growth Strategies, Including Strategic and Financing Alternatives
Company Believes It Met Every Key Objective for Its Product Launch, Reiterates Expectation to Secure One or More Strategic Marketing/Sales Partners by Year's End, and Reaffirms Guidance for Sales of Its New PCT Microplate Strip System to Begin in the 2H 2014